CRANBURY, N.J., Aug. 22, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the ...
The effectiveness of phosphodiesterase-5 (PDE-5) inhibitors in treating erectile dysfunction (ED) caused by a wide range of etiologies has functionally created a new field of medicine. 1 However, ...
PT-141, a cyclic heptapeptide melanocortin analog, was evaluated following subcutaneous administration to healthy male subjects and to patients with erectile dysfunction (ED) who report an inadequate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results